Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.

Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.

SCS is a form of neuromodulation therapy that addresses pain in regions including the limbs, trunk, and neck. Credit: Marbury/Shutterstock.com The UK’s Newcastle Hospitals National Health Service (NHS ...

The PRIMA implant held between tweezers. Credit: Science Corporation / Business Wire. Brain-computer interface (BCI) company Science Corporation has launched its Prima device commercially in Europe ...

Affinity Technologies has collaborated with Pictor to develop and commercialise new diagnostic tests for asthma and COPD.

The AHAs report on Ultromics’ AI tool found that it could detect heart failure and preserved ejection fraction (HFpEF) up to nine months earlier than standard clinical care. Credit: ...

While not disclosing a specific launch timeframe, with de novo clearance in hand, J&J initially plans to launch Ottava with “select customers”.

Following TYBR’s B3 GEL’s US launch in January 2026, the company primarily intends to use the funds to expand market access to the hydrogel.

Health technology brand Hilo, developed by Aktiia, has launched its Hilo Core blood pressure monitoring system in the US.

Cardinal Health’s acquisitions of Strive Medical and Adapt Health’s diabetes unit are collectively intended to support its at-home care business’s growth strategy.

Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.